STOCK TITAN

SKINVISIBLE INC - $SKVI STOCK NEWS

Welcome to our dedicated page for SKINVISIBLE news (Ticker: $SKVI), a resource for investors and traders seeking the latest updates and insights on SKINVISIBLE stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SKINVISIBLE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SKINVISIBLE's position in the market.

Rhea-AI Summary
Skinvisible, Inc. (SKVI) announces positive progress in clinical trials for Netherton Syndrome treatment with licensee Quoin Pharmaceuticals, Inc. (QNRX). Promising initial data and safety profile lead to optimization plan implementation and protocol amendments for potential regulatory approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
none
SKINVISIBLE INC

OTC:SKVI

SKVI Rankings

SKVI Stock Data

458.52k
4.35M
3.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Las Vegas

About SKVI

skinvisible, inc., through its wholly owned subsidiary, skinvisible pharmaceuticals, inc., is an r&d pharmaceutical company that develops enhanced, patented dermatology and healthcare products to treat skin conditions from acne to warts, along with sunscreens, anti-aging products, hand sanitizing lotions, pre-surgical preparations, and medical treatments outside of dermatology using its patented technology invisicare®. skinvisible's primary objective is to license these prescription and over-the-counter products into the global dermatology and medical markets. potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products or life cycle management for their existing products. www.invisicare.com and www.skinvisible.com